对比增强68Ga-FAPI-04 PET/MRI较18F-FDG PET/CT在肝细胞癌中的附加价值
一例43岁慢性乙型肝炎伴甲胎蛋白升高的男性患者,18F-FDG PET/CT未见恶性证据,随后68Ga-FAPI-04 PET/MR显示肝内病灶FAPI摄取增高并伴MRI详细强化模式,诊断为肝细胞癌并经病理证实。本病例提示整合68Ga-FAPI-04 PET与增强MRI在优化肝细胞癌诊断中的作用,较传统模态提供更细致的影像学评估方法。
要点
- 18F-FDG PET/CT阴性时,68Ga-FAPI-04 PET/MR可显示肝内FAPI摄取增高病灶。
- 68Ga-FAPI-04 PET/MR结合MRI增强模式有助于肝细胞癌诊断,并经病理证实。
- 整合68Ga-FAPI-04 PET与增强MRI可较传统模态提供更细致的肝脏病灶评估。
核心结论
- 整合68Ga-FAPI-04 PET与增强MRI在优化肝细胞癌诊断中具有关键作用,较传统模态提供更细致的影像学评估方法。
研究设计与样本
- 个案报道:一名43岁慢性乙型肝炎伴甲胎蛋白升高的男性患者,先后接受18F-FDG PET/CT与68Ga-FAPI-04 PET/MR检查,诊断经病理证实。
主要发现
- 18F-FDG PET/CT未见恶性证据。
- 68Ga-FAPI-04 PET/MR显示肝内病灶FAPI摄取增高,并伴MRI详细强化模式,诊断为肝细胞癌,后经病理证实。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 43-year-old man with chronic hepatitis B and elevated alpha-fetoprotein levels showed no malignant evidence on 18 F-FDG PET/CT. However, subsequent assessment using 68 Ga-FAPI-04 PET/MR identified a lesion with increased FAPI uptake in the liver, coupled with detailed enhancement patterns on MRI, leading to a diagnosis of hepatocellular carcinoma, later confirmed by pathology. This case highlights the pivotal role of integrated 68 Ga-FAPI-04 PET and enhanced MRI in refining hepatocellular carcinoma diagnostics, advancing a more nuanced imaging approach over conventional modalities for comprehensive evaluation of hepatic lesions.
引用
- Ding J, Zhao J, Chen X, et al. The Added Value of Contrast-Enhanced 68 Ga-FAPI-04 PET/MRI Over 18 F-FDG PET/CT in Hepatocellular Carcinoma. Clin Nucl Med. 2024. PMID: 38914096. doi:10.1097/RLU.0000000000005342
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。